- CEO
- Qun Zhao
- Full Time Employees
- 1,162
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Room 3605-3610 Datong SX China 200232
- IPO Date
- Aug 5, 2011
- Business
- ShanXi C&Y Pharmaceutical Group Co., Ltd. (300254.SZ) is a pharmaceutical company engaged in the research, development, production, and sale of medicines, health foods, and related medical services. The company offers a diverse portfolio of products including anti-infective drugs; anti-allergic drugs such as Ebastine tablets; respiratory system drugs like Ambroxol hydrochloride dispersible tablets and Montmorillonite powder; urinary system drugs including Tamsulosin hydrochloride sustained release capsules; kidney disease drugs such as Cinacalcet hydrochloride tablets; children's medicines like Vitamin AD drops; cardiovascular and cerebrovascular drugs; antidepressants including Fluoxetine hydrochloride capsules; smoking cessation drugs such as Varenicline tartrate tablets; pharmaceutical raw materials and intermediates; and Baoling Jingbao oral liquid. It also provides medical and health services encompassing medical diagnosis, gene preservation, pregnancy environment testing, and clinical laboratory services through subsidiaries.
Founded in 2005 as Shanxi Qianyuan Pharmaceutical Co., Ltd., the company, headquartered in Shanghai, China, listed on the Shenzhen Stock Exchange GEM in August 2011 and changed its name to ShanXi C&Y Pharmaceutical Group Co., Ltd. in September 2014. Operations span multiple segments including medicine, health food, and services, with geographic revenue primarily from East China, Central China, North China, South China, Southwest China, Northwest China, and Northeast China, alongside minor overseas sales. The company maintains production bases and subsidiaries such as Hangzhou Baoling Pharmaceutical, Zhejiang Hailisheng Pharmaceutical, Jiangsu Jiayi Pharmaceutical, Hangzhou Ens hi Gene, Sichuan Qianyuan Traditional Chinese Medicine, Wuxi Lianhe Likang Clinical Laboratory, and Tibet Qianyuan, supporting its focus on chemical synthesis drugs, biological drugs, natural drugs, APIs, intermediates, traditional Chinese medicines, and healthcare products.
In recent years, ShanXi C&Y Pharmaceutical Group has pursued strategic expansions, including the 2016 acquisition of Wuxi Lianhe Likang Clinical Laboratory Co., Ltd. to bolster its medical testing capabilities, and a 2020 strategic shift to emphasize high-end pharmaceuticals as the core business with precision medicine and health foods as key wings. The company continues to optimize its product structure through mergers, investments, and R&D enhancements via its advanced drug research institute, while extending services across 34 provincial administrative regions in China and into international markets. As of 2025, it employs over 1,600 people and reports ongoing involvement in innovative drug developments amid industry trends like commercial insurance payments and overseas authorizations.